Merge to post results below expectationsDisappointing direct and OEM/VAR sales for Merge Technologies during its fourth quarter will apparently result in financial results below analyst projections. For the period, the Milwaukee, WI-based
Disappointing direct and OEM/VAR sales for Merge Technologies during its fourth quarter will apparently result in financial results below analyst projections. For the period, the Milwaukee, WI-based company expects to have revenue between $2 million and $2.3 million, compared with revenue of $2.9 million for the same period last year. Merge believes its net loss will be between 19¢ and 22¢ per share. First Call had expected a profit of 2¢ per share for the quarter.
For the year, Merge expects revenue to be between $9.4 million and $9.7 million, compared with $9.7 million posted in 1997. The firm expects a net loss of 35¢ to 38¢ cents per share, compared with a net loss of 5¢ recorded last year.
Merge's stock closed at a price of $1.25 on January 15, down nearly 80% from its IPO price of $6 in January 1998. The company is reorganizing its sales staff to address its end-user sales difficulties and is redoubling its efforts to improve its OEM/VAR efforts, said president and CEO William Mortimore.
As part of that strategy, the company has signed an agreement with ADAC Laboratories of Milpitas, CA, in which ADAC will expand its distribution of Merge DICOM products.
In other OEM news, GE Medical Systems of Milwaukee, WI, has signed an annual master's license for Merge's MergeCOM-3 software. GE will use the software to convert proprietary image data within its medical imaging products to DICOM 3.0 format.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.